MGC Pharma expands CannEpil sales in UK and Australia


Updated 17 April 2019 to include purchase order figures.

MGC Pharma (ASX: MXC, OTC: MGCLF) is increasing their distribution of medicinal cannabis products both in the UK and Australia.

In the UK, a permit under their Controlled Drug Import Licence has been issued for the importation fo CannEpil – MGC’s flagship product for the treatment of sever retractable epilepsy. With an initial purchase order to meet, this allows MGC to immediately expand their distribution into the UK, which will be handled by their distribution partner, Lenis.

In Australia, MGC has received has additional purchase orders worth over AUD $200,000, which will initiate further imports and subsequent commercial distribution. The increase of MGC commercialisation in Australia will be relief for shareholders, who have been waiting to see their products since GMP certification last year.

MGC Managing Director Roby Zomer said, “We are delighted to have received this Permit from the United Kingdom Home Office Drugs Licencing and Compliance Unit, as it significantly expands the potential distribution of CannEpil into the UK. With first purchase orders from the UK and Australian licensed distribution partners already received, and new distribution deals expected to be signed in the coming weeks, our expanded distribution in Australia, Europe and the UK will mean we will be able to provide more patients in need with access to CannEpil and our other IMPs”.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Blaise Bratter
Blaise Bratter is the Chief Contributor to CannabisIntel. Being involved in the Australian cannabis industry since legalisation in 2016, he is now Operations Manager for ASX listed company MGC Pharmaceuticals.

Get all the latest content delivered straight to your inbox.”